The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Coherus BioSciences sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Coherus BioSciences Inc, United States Revenue

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Coherus BioSciences Inc (Coherus) is a biopharmaceutical company that conducts research, development and commercialization of immunotherapies to treat cancer. The company markets Udenyca (pegfilgrastim-cbqv), a biosimilar of Neulasta, and Cimerli (ranibizumab-eqrn), a biosimilar of Lucentis, in the US. Coherus products find its application for the treatment of various therapeutic areas which includes nasopharyngeal carcinoma, hepatocellular carcinoma, non-small lung cancer, small cell lung cancer and solid tumors. It is evaluating Toripalimab’s pivotal clinical trial for the treatment of nasopharyngeal carcinoma. The company also plans to launch Humira, a biosimilar Yusimry (adalimumab-aqvh) in the current fiscal year. It collaborates with other organizations to develop drug candidates. Coherus is headquartered in Redwood City, California, the US. Key subsidiaries of Coherus BioSciences include Coherus Oncology, Coherus Intermediate, InteKrin Russia, Orphonix and InteKrin Therapeutics.

The key metrics of Coherus BioSciences related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:

As Coherus BioSciences is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Coherus BioSciences.

For a detailed understanding of the performance of Coherus BioSciences, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.